Galectin Therapeutics (NASDAQ: GALT), a development stage company, is the world’s leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and to alleviate the side-effects of chemotherapy.
- Galectin Therapeutics5.08+0.50 +10.92%
- WP Stock Ticker
To show sotck chart
Headquartered in the burgeoning biotech center of Atlanta, Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. The Company’s chief scientist literally wrote the first book ever published on the subject of galectins, and we are leveraging our team’s unparalleled expertise in this area as well as established relationships with external sources to achieve cost effective and efficient development as we pursue these groundbreaking technologies. We are currently in Phase I/II cancer immunotherapy trials in Europe in conjunction with the prestigious Ludwig Institute, and Phase I/II trials in the United States with our liver fibrosis drug.